What Drives the 7.4% Growth in India's Pharma Market in April?
Click to start listening
Synopsis
Discover the factors contributing to the impressive 7.4% growth in India's pharma market for April. Chronic therapies are on the rise, revealing trends that could shape the future of healthcare in the country. Stay informed on the dynamics of the pharmaceutical industry and what it means for patients and businesses alike.
Key Takeaways
- 7.4% YoY growth in India's pharma market for April.
- Chronic therapies are a significant driver of growth.
- Domestic companies hold 83% market share.
- Acute therapies show 6% YoY growth.
- Key therapies include cardiac, CNS, and respiratory.
New Delhi, May 15 (NationPress) The Indian pharma market (IPM) experienced a remarkable 7.4% year-on-year (YoY) growth in April, primarily fueled by an increase in chronic therapies, as revealed in a recent report.
The monthly analysis by Motilal Oswal Financial Services indicated that the IPM's growth for April 2024 was recorded at 9%, while it reached 9.3% in March 2025.
This growth trajectory was largely attributed to outstanding performance in cardiac, central nervous system (CNS), and respiratory therapies.
Significantly, the respiratory therapies sector witnessed a resurgence in YoY growth during April. The growth for acute therapies was noted at 6% in April, mirroring the same percentage from April 2024 but down from 8% in March 2025, attributed to seasonality.
The driving forces behind the IPM growth included price increases (4.3%), new product launches (2.3%), and volume growth (1.3%).
Furthermore, the report highlighted that therapies such as cardiac (11.3%), gastro (9.4%), antineoplastic (also known as anticancer drugs or chemotherapy drugs) (12.6%), and urology (13.1%) led the YoY growth on a moving annual turnover (MAT) basis. The industry recorded a 7.9% YoY growth based on MAT.
Chronic therapies showed a 9% YoY growth, while acute therapies recorded 6% YoY growth in April. The acute segment accounted for 61% of the overall IPM during MAT April, with a YoY growth of 7.9%.
The report also indicated that domestic companies outperformed multinational corporations in April. As of April, Indian pharma firms held a dominant 83% share of the IPM, with the remaining percentage attributed to multinational pharma companies (MNCs). In March, Indian companies grew by 7.4%, compared to 7.4% growth for MNCs YoY.
In addition, a recent report from the rating agency India Ratings and Research (Ind-Ra) confirmed that the IPM maintained its growth momentum in April, achieving 7.8% YoY revenue growth.
This growth was propelled by price increases implemented by companies, with volume growing by 1.3% YoY. Nearly all major chronic therapies demonstrated positive value and volume growth.
Point of View
It's imperative to recognize the resilience and adaptability of the Indian pharmaceutical sector. The reported growth amidst challenging market conditions reflects the industry's commitment to innovation and patient care, positioning India as a pivotal player in global healthcare. We stand by the nation's achievements and continue to support the pharma industry's evolution.
NationPress
13/06/2025
Frequently Asked Questions
What contributed to the growth of the Indian pharma market in April?
The growth of the Indian pharma market in April was largely driven by a surge in chronic therapies, particularly in cardiac, CNS, and respiratory therapies.
How did domestic companies perform compared to multinational companies?
Domestic companies outperformed multinational companies in April, holding an 83% share of the Indian pharma market.
What was the YoY growth rate for acute therapies?
The acute therapies segment recorded a YoY growth rate of 6% in April.
What are the key therapies driving the growth?
Key therapies driving the growth include cardiac therapy, gastro therapy, antineoplastic therapy, and urology therapy.
What was the reported YoY growth for chronic therapies?
Chronic therapies witnessed a YoY growth of 9% in April.
